You are here

Article info

Article menu

Download PDFPDF

XML
Hepatology
Original article
Oncolytic reovirus as a combined antiviral and anti-tumour agent for the treatment of liver cancer

Authors

  • Adel Samson Leeds Institute of Cancer & Pathology (LICAP) and Leeds Cancer Research UK Clinical Centre, Faculty of Medicine and Health, University of Leeds, St James’ University Hospital, Leeds, UK PubMed articlesGoogle scholar articles
  • Matthew J Bentham Leeds Institute of Cancer & Pathology (LICAP) and Leeds Cancer Research UK Clinical Centre, Faculty of Medicine and Health, University of Leeds, St James’ University Hospital, Leeds, UK PubMed articlesGoogle scholar articles
  • Karen Scott Leeds Institute of Cancer & Pathology (LICAP) and Leeds Cancer Research UK Clinical Centre, Faculty of Medicine and Health, University of Leeds, St James’ University Hospital, Leeds, UK PubMed articlesGoogle scholar articles
  • Gerard Nuovo The Ohio State University, Comprehensive Cancer Centre, Columbus, Ohio, USA PubMed articlesGoogle scholar articles
  • Abigail Bloy Leeds Institute of Cancer & Pathology (LICAP) and Leeds Cancer Research UK Clinical Centre, Faculty of Medicine and Health, University of Leeds, St James’ University Hospital, Leeds, UK PubMed articlesGoogle scholar articles
  • Elizabeth Appleton Leeds Institute of Cancer & Pathology (LICAP) and Leeds Cancer Research UK Clinical Centre, Faculty of Medicine and Health, University of Leeds, St James’ University Hospital, Leeds, UK PubMed articlesGoogle scholar articles
  • Robert A Adair Leeds Institute of Cancer & Pathology (LICAP) and Leeds Cancer Research UK Clinical Centre, Faculty of Medicine and Health, University of Leeds, St James’ University Hospital, Leeds, UK PubMed articlesGoogle scholar articles
  • Rajiv Dave Leeds Institute of Cancer & Pathology (LICAP) and Leeds Cancer Research UK Clinical Centre, Faculty of Medicine and Health, University of Leeds, St James’ University Hospital, Leeds, UK PubMed articlesGoogle scholar articles
  • Adam Peckham-Cooper Leeds Institute of Cancer & Pathology (LICAP) and Leeds Cancer Research UK Clinical Centre, Faculty of Medicine and Health, University of Leeds, St James’ University Hospital, Leeds, UK PubMed articlesGoogle scholar articles
  • Giles Toogood Leeds Institute of Cancer & Pathology (LICAP) and Leeds Cancer Research UK Clinical Centre, Faculty of Medicine and Health, University of Leeds, St James’ University Hospital, Leeds, UK PubMed articlesGoogle scholar articles
  • Seishi Nagamori PubMed articlesGoogle scholar articles
  • Matthew Coffey Department of Virology II, National Institute of Infectious Diseases 1-23-1 Toyama, Tokyo, Japan Oncolytics Biotech, Calgary, Alberta, Canada PubMed articlesGoogle scholar articles
  • Richard Vile Leeds Institute of Cancer & Pathology (LICAP) and Leeds Cancer Research UK Clinical Centre, Faculty of Medicine and Health, University of Leeds, St James’ University Hospital, Leeds, UK Department of Immunology, Mayo Clinic, Rochester, Minnesota, USA Department of Molecular Medicine, The Institute of Cancer Research, London, UK PubMed articlesGoogle scholar articles
  • Kevin Harrington Department of Molecular Medicine, The Institute of Cancer Research, London, UK PubMed articlesGoogle scholar articles
  • Peter Selby Leeds Institute of Cancer & Pathology (LICAP) and Leeds Cancer Research UK Clinical Centre, Faculty of Medicine and Health, University of Leeds, St James’ University Hospital, Leeds, UK PubMed articlesGoogle scholar articles
  • Fiona Errington-Mais Leeds Institute of Cancer & Pathology (LICAP) and Leeds Cancer Research UK Clinical Centre, Faculty of Medicine and Health, University of Leeds, St James’ University Hospital, Leeds, UK PubMed articlesGoogle scholar articles
  • Alan Melcher Department of Molecular Medicine, The Institute of Cancer Research, London, UK PubMed articlesGoogle scholar articles
  • Stephen Griffin Leeds Institute of Cancer & Pathology (LICAP) and Leeds Cancer Research UK Clinical Centre, Faculty of Medicine and Health, University of Leeds, St James’ University Hospital, Leeds, UK PubMed articlesGoogle scholar articles
  1. Correspondence to Dr Stephen Griffin and Prof Alan Melcher, Faculty of Medicine and Health, Leeds Institute of Cancer & Pathology, University of Leeds, Wellcome Trust Brenner Building, St James’ University Hospital, Leeds LS7 9TF, UK; s.d.c.griffin{at}leeds.ac.uk and a.a.melcher{at}leeds.ac.uk
View Full Text

Citation

Samson A, Bentham MJ, Scott K, et al
Oncolytic reovirus as a combined antiviral and anti-tumour agent for the treatment of liver cancer
Gut 2018;67:562-573.

Publication history

  • Received April 6, 2016
  • Revised September 26, 2016
  • Accepted October 13, 2016
  • First published November 15, 2016.
Online issue publication 
June 23, 2018

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/ This is an Open Access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 4.0) license, which permits others to distribute, remix, adapt and build upon this work, for commercial use, provided the original work is properly cited. See: http://creativecommons.org/licenses/by/4.0/